Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

NIH 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 3Sarcoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neoplasm Metastasis 2Gliosarcoma 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Astrocytoma 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Glioma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1

Interventions

aldesleukin 65Cyclophosphamide 45fludarabine phosphate 30fludarabine 27Interleukin-2 24incomplete Freund's adjuvant 22Ipilimumab 17Specimen Handling 14MART-1 Antigen 14CTLA-4 Antigen 14sargramostim 13Magnetic Resonance Spectroscopy 13Biopsy 13montanide ISA 51 11Nivolumab 11Filgrastim 11Sorafenib 10Interferon-alpha 9trametinib 8pembrolizumab 8dabrafenib 8Sirolimus 7Bevacizumab 7temsirolimus 6Temozolomide 6Taxes 5Paclitaxel 5Introns 5Gene Expression Profiling 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Melanoma × aflibercept × Clear all
NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
59 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT01258855 2019-05-10

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled 13 charts
Dermatologic

Melanoma

NCT00450255 2018-05-24

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 7 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡